Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 21.60 |
---|---|
High | 21.60 |
Low | 21.60 |
Bid | 21.40 |
Offer | 22.00 |
Previous close | 21.20 |
Average volume | -- |
---|---|
Shares outstanding | 661.77m |
Free float | 655.42m |
P/E (TTM) | 19.18 |
Market cap | 15.78bn USD |
EPS (TTM) | 1.26 USD |
Data delayed at least 15 minutes, as of Sep 27 2024 07:04 BST.
More ▼
- Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
- TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
- Genmab Announces Changes to its Executive Committee
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Genmab Announces Financial Results for the First Half of 2024
- Genmab Updates 2024 Financial Guidance
- Genmab Takes Full Control of Acasunlimab Development Program
More ▼